Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Placebo-Controlled Study of Two Treatment Strategies Based on Tocilizumab (TCZ) With or Without Methotrexate (MTX) and Possible Addition of Other Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Patients With Active Rheumatoid Arthritis Who Have Inadequately Responded to Prior MTX Treatment

Trial Profile

Randomized Placebo-Controlled Study of Two Treatment Strategies Based on Tocilizumab (TCZ) With or Without Methotrexate (MTX) and Possible Addition of Other Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Patients With Active Rheumatoid Arthritis Who Have Inadequately Responded to Prior MTX Treatment

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tocilizumab (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms ACT-RAY
  • Sponsors Roche
  • Most Recent Events

    • 26 Aug 2020 Results of a pooled analysis from twelve phase 3 and 4 clinical trials: ACT-RAY, ACT-STAR, ACT-SURE, ADACTA, AMBITION, BREVACTA, COMP-ACT, LITHE, OPTION, ROSE, SUMMACTA and TOWARD assessing predictors of response, including demographics, disease characteristics at baseline published in the Rheumatology
    • 06 Jun 2020 Results of pooled analysis from seven studies (OPTION, RADIATE, TOWARD, LITHE, ACT-RAY, ADACTA and BREVACTA) presented at the 21st Annual Congress of the European League Against Rheumatism.
    • 07 Feb 2020 Results (n=1750) of post hoc analysis determining if inclusion of patients on background GC use influences efficacy and safety outcomes of RA randomised clinical trials from AMBITION, ACT-RAY, ADACTA and FUNCTION on initiation of tocilizumab (TCZ) or adalimumab (ADA) or methotrexate (MTX) monotherapy. published in the Annals of the Rheumatic Diseases
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top